Articles by Neel Chudgar, MD
Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD Conclusion of the discussion and award presentation.
Optimal Approach for PD-L1 >50%
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.
Treatment for Borderline Resectable Patients With NSCLC
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD Discussion on the treatment for borderline resectable patients with NSCLC.
Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.
Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.
Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer
Introduction of the Debate Between Jets v. Giants
ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD An outline of the debate, the speakers, and the basic guidelines to support the program.
